Logo image
Sign in
Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials
Journal article   Peer reviewed

Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials

Frédéric Fiteni
Lancet Oncology, Vol.23(11)
11/2022
PMID: 36328009

Abstract

Humans Female Quality of Life Carcinoma, Ovarian Epithelial Ovarian Neoplasms
Ignace Vergote and colleagues published consensus recommendations on methodological aspects of ovarian cancer clinical trials, which constitute a great achievement to harmonise their designs and will represent a valuable resource for ovarian cancers investigators.
url
Find in HALView

Metrics

1 Record Views

Details

Logo image